Please excuse the poor formatting above. Double-clicked when I shouldn't have. Here's something else I found that may be of interest:
As of Mar 21, 2015, the consensus forecast amongst 4 polled investment analysts covering Epirus Biopharmaceuticals Inc. advises investors to purchase equity in the company. This has been the consensus forecast since the sentiment of investment analysts improved on Jul 21, 2014. The previous consensus forecast advised investors to hold their position in Epirus Biopharmaceuticals Inc.
You can get on the bus or remain at the station. Do your own DD. The biosimilar market is getting quite interesting.
Closed a $36 million Series B financing round
Completed merger with Zalicus Inc.; Gained
public listing on Nasdaq:EPRS
Entered into a multi-product collaboration
agreement with Livzon Mabpharm for China
BOW015 approved and launched in first
market, India, under the trade name Infimab™
In 2015 and beyond:
Completed $52.8M follow on offering – 1Q15
BOW015 additional market filings and partnerships (LATAM, Asia) – Filings throughout 2015
BOW050 partnership(s) – 1H15
BOW015 US / EU partnership – 2H15
Initiation of BOW015 global phase 3 – 4Q15/1Q16
BOW050 enters clinical trials – 2H16
BOW015 launches in multiple South East Asian markets – throughout 2016
What do you know. The stock is up a couple of bucks since I last visited here. Hopefully, we'll hear some good news when they report next week on the 12th.
TTMA as someone here used to say!
Isn't an investment in any stock hopeful?
You mention one of their partners (Ranbaxy) that will be sharing the proceeds but leave out others like Reliance Life Sciences (RLS), Fujifilms and Livzon. RLS will be the actual manufacturer in India. Ranbaxy is a partner that affords them real good access due to their size and exposure to 150 countries.
How about their trademarked SCALE platform? It allows for multiple biosimilar drugs to be made in the same facility which will cut manufacturing costs effectively.
The reasons for partnering with all these different entities: there are basically three types of drug Markets. Developed, Local Production and Accessible. These all of have specific rules such as where the medicine must be produced or tested (e.g., locally). An accessible market, such as India, will furnish EPRS with an Indian regulatory package. The regulatory filing from India MAY be all that is needed to allow the drug to be sold in a country like Brazil, without any phase testing whatsoever. The Indian regulatory package is readily accepted in countries such as Africa, southeastern Asia and South & Central America (excluding Brazil).
Livzon is their Chinese partner and they have invested heavily in EPRS already, during the IPO.
So yes, I guess you could say that I have "hopium". I also don't plan on selling any time soon. Just want other ZBAers to look into what EPRS is doing and how they are laying the groundwork. They appear to be creating a rather large scale plan. My opinion only.
I would bet that more than 99% of us know the whole story. Former ZLCS holders that are still here are the ones that are praying for a turnaround.
- EPRS also hooked up with ZLCS because they knew the "ropes" in getting listed quickly for funding purposes.
- Wrong-way Corrigan has some expertise in getting a drug to market (Exalgo) and how to navigate through phase approvals.
- ZLCS was well respected at one time, had some cash to give out and did have connections in certain areas.
- EPRS stock has taken off at times due to India approval of BOW015 and future European phase 3 approval. They also have Asian, African, etc. markets as near term market possibilities.
- The biosimilar drugs that EPRS has in its stable are "big money maker" name brands (Remicade, Humira and Actemra).
There are probably some other points that I cannot think of off hand but these seem to be some of the main reasons for the price spikes.
Which is exactly why I, a Zalicus holdover who is down some bucks, decided to add shares of EPRS a few months ago. I figured it was the only way I could regain some of my losses. I did the same thing with SUV a few years ago and went from the out house to the bank. All of you former big 'Z'ers should think about getting your feet wet again. This is just my opinion, and think of all the fun you'll have again. Sleepless nights, worrying about whether or not the drug will pass phase 3, etc. Heck, the Dawg may even show himself again and entertain us with a lot of his research that he's done on biosimilars over the past couple of years. Food for thought!
My old ZLCS average was around $68 for break even, but then I had a premonition and wound up buying some more shares later when they were around $3.70. That took my average down to $38 afterwards. I'm getting closer to breaking even and hopefully I'll be able to finally bail on this after we have some sales in India. Keep going Zalicepirus!!!
Does this even have a chance to occur in 2014?
EPIRUS is a Boston-based, privately held company, backed by Montreux Equity Partners, TPG
Biotech, and 5AM Ventures. EPIRUS is developing a broad pipeline of biosimilars for commercialization in major emerging markets. Our first product is BOW015, a biosimilar to Remicade®. BOW015 has successfully completed P1 and P3 clinical trials. We anticipate first market approval and launch in 2014.